Galera Therapeutics downgraded by HC Wainwright & Co.
$GRTX
Biotechnology: Pharmaceutical Preparations
Health Care
HC Wainwright & Co. downgraded Galera Therapeutics from Buy to Neutral
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/10/2023 | $6.00 → $0.50 | Overweight → Neutral | Piper Sandler |
| 12/20/2021 | $11.00 → $20.00 | Buy | Citigroup |
| 12/15/2021 | $10.00 | Neutral → Buy | HC Wainwright & Co. |
| 12/15/2021 | $15.00 | Neutral → Buy | BTIG |
| 10/20/2021 | Buy → Neutral | HC Wainwright & Co. | |
| 10/19/2021 | $17.00 → $2.00 | Buy → Underperform | BofA Securities |
| 10/19/2021 | Buy → Neutral | BTIG Research |
Galera's development strategy shifts from toxicity reduction to anti-cancer therapeutics, with three trials in patients with highly resistant subsets of advanced breast cancer. Lead program is Phase 1/2 trial of Nova Pharmaceutical's Clinical Stage Nitric Oxide Synthase (NOS) Inhibitor on top of standard-of-care nab-paclitaxel and alpelisib in metaplastic breast cancer. Concurrent financing when added to Galera's existing cash balance, is anticipated to fund operations through data readout of its lead program and into 2026. Galera intends to leverage NCI grants, academic partnerships and the I-SPY 2 network for efficient and cost-effective clinical dataset expansion. MALVERN, Pa.
MALVERN, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX), a clinical-stage biopharmaceutical company historically focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that its Board of Directors has approved a Plan of Liquidation and Dissolution (Plan of Dissolution), which provides for the dissolution of the Company under Delaware law, and plans to seek stockholder approval of the Plan of Dissolution at a special meeting of stockholders to be held on or around October 17, 2024. If the Plan of Dissolution is approved by the Company's stockholders, the Company intends t
MALVERN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the first quarter ended March 31, 2024, and provided recent corporate updates. "Our review of strategic options continues, as we strive to maximize value for our stockholders," said Mel Sorensen, M.D., Galera's President and CEO. "Potential options may include mergers, asset sales, divestiture, licensing arrangements, or other strategic transactions and may encompass a potential development path
4 - Galera Therapeutics, Inc. (0001563577) (Issuer)
4 - Galera Therapeutics, Inc. (0001563577) (Issuer)
4 - Galera Therapeutics, Inc. (0001563577) (Issuer)
Piper Sandler downgraded Galera from Overweight to Neutral and set a new price target of $0.50 from $6.00 previously
Citigroup reiterated coverage of Galera Therapeutics with a rating of Buy and set a new price target of $20.00 from $11.00 previously
HC Wainwright & Co. upgraded Galera Therapeutics from Neutral to Buy and set a new price target of $10.00
4 - Galera Therapeutics, Inc. (0001563577) (Issuer)
4/A - Galera Therapeutics, Inc. (0001563577) (Issuer)
4 - Galera Therapeutics, Inc. (0001563577) (Issuer)
10-Q - Galera Therapeutics, Inc. (0001563577) (Filer)
8-K - Galera Therapeutics, Inc. (0001563577) (Filer)
10-K - Galera Therapeutics, Inc. (0001563577) (Filer)